Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C [1]

Hepatology

Volumn 36, Issue 4 I, 2002, Pages 1022-

  Terui, Yuki ^a   Saito, Takafumi ^a   Watanabe, Hisayoshi ^a   Togashi, Hitoshi ^a   Kawata, Sumio ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLLAGEN TYPE 4; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

ADULT; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; LETTER; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN;

EID: 18644369234     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32679     Document Type: Letter

References (10)

1. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-1156.
2. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Kishida H, et al. Angiotensin II type I receptor interaction is a major regulation for liver fibrosis development in rats. Hepatology 2001;34:745-750.
3. Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984;4:830-834.
4. Tsushima H, Kawata S, Tamaru S, Ito N, Shirai Y, Kiso S, Doi Y, et al. Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis. J Hepatol 1999;30:1-7.
5. Schneider AW, Falk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-339.
6. Gonzalez-Abraldes J, Albillos A, Banares R, Arbol LRD, Moitinho E, Rodriqueez C, Gonzalez M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-388.
7. Schepke M, Werner EVA, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbestatin in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-395.
8. Schuppan D, Hahn EG. Interleukin 10: the magic bullet for liver fibrosis. Gastroenterology 2000;119:1412-1413.
9. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omara M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-564.
10. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997;26(Suppl 1):143S-151S.